Quick Answer
Matinas BioPharma Holdings, Inc. reported Operating Income Loss of -$6.96 million for the year ending 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +71.7% in Operating Income Loss from 2024 to 2025.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Matinas BioPharma Holdings, Inc.'s Operating Income Loss has declined by 87.5%.
- Historical annual values: Fiscal year 2025: -$6.96 million | Fiscal year 2024: -$24.59 million | Fiscal year 2023: -$23.77 million | Fiscal year 2022: -$24.59 million | Fiscal year 2021: -$24.74 million | Fiscal year 2020: -$24.21 million | Fiscal year 2019: -$18.92 million | Fiscal year 2018: -$14.65 million | Fiscal year 2017: -$16.50 million | Fiscal year 2016: -$8.26 million | Fiscal year 2015: -$9.91 million | Fiscal year 2014: -$10.46 million | Fiscal year 2013: -$3.71 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: